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Tumour sequencing identifies highly recurrent point mutations in cancer driver genes, but rare 
functional mutations are hard to distinguish from large numbers of passengers. We developed a novel 
computational platform applying a multi-modal approach to filter out passengers and more robustly 
identify putative driver genes. The primary filter identifies enrichment of cancer mutations in CATH 
functional families (CATH-FunFams) – structurally and functionally coherent sets of evolutionary related 
domains. Using structural representatives from CATH-FunFams, we subsequently seek enrichment 
of mutations in 3D and show that these mutation clusters have a very significant tendency to lie close 
to known functional sites or conserved sites predicted using CATH-FunFams. Our third filter identifies 
enrichment of putative driver genes in functionally coherent protein network modules confirmed by 
literature analysis to be cancer associated. Our approach is complementary to other domain enrichment 
approaches exploiting Pfam families, but benefits from more functionally coherent groupings of 
domains. Using a set of mutations from 22 cancers we detect 151 putative cancer drivers, of which 79 
are not listed in cancer resources and include recently validated cancer associated genes EPHA7, DCC 
netrin-1 receptor and zinc-finger protein ZNF479.
Advances in technology have made exome and whole-genome sequencing commonplace and have been catalysts 
for large-scale concerted cancer genome sequencing efforts such as TCGA1 and ICGC2. In tandem with details 
of tumour types, histology, treatments and patient outcomes, these sequences provide unique opportunities for 
identifying which mutations and genes drive tumour expansion and how these vary between cancer types.
Mutations observed in tumours may be drivers, positively influencing tumour progression, or passengers, 
which are incidental and have no net effect3. Methods such as MutSigCV4 analyse somatic mutations from tumour 
samples to identify sequence positions mutated above a significance threshold using a sophisticated model of 
background mutation rates. However, finding driver genes using individual point mutations lacks the statistical 
power to uncover many driver genes as the heterogeneous mutation landscape of cancer genomes leads to many 
genes having few mutations, thus identifying significant point mutations requires many tumour samples3. A com-
plementary approach is to analyse mutations by mapping to 3D protein structures. Structural studies can help 
identify mutations clustering in specific regions of a protein and highlight cases where rare mutations - that may 
lie far apart in sequence - are close together when mapped to residues in the protein’s structure. Multiple recent 
methods aid driver gene identification using structure-based algorithms: by calculating frequencies of distances 
between mutated residue pairs5; calculating a clustering coefficient using weighted sums of mutated pairs6,7; using 
permutation testing of mutation distance distributions8; finding mutational hotspots within spherical regions9–12 
and testing protein complexes13,14.
Other developments to enhance driver gene detection, that focus on regions in the protein, include clustering 
of mutations on sequence regions15 or using Pfam16 protein domains10,17–19. As evolutionarily-related, discrete & 
independently folding units of sequence, domains are often found in multiple genes and in different contexts (i.e. 
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multiple domain architectures), therefore domain enrichment may enhance both the statistical power for driver 
detection and allow clearer prediction of the functional impacts of mutations20–22. Sequence hotspots can be 
detected more easily in enriched domains10,17,19,23,24 and can be analysed using co-location with functional sites19 
such as catalytic sites25, phosphosites26 and protein-protein interface (PPI) residues27–32. The distribution of can-
cer mutations to functional sites can be compared with polymorphisms obtained from UniProt33. For example, 
Skolnic et al.30 found an enrichment of disease-causing mutations at functional sites or at ligand-biding sites adja-
cent to PPIs. Other studies assess how mutation proximity to functional sites varies between known oncogenes 
and TSGs6,34.
Network approaches can also be used to interpret genes implicated in cancer in terms of cellular processes35. 
In particular, multiple genes containing mutations in a tumour sample may belong to different components of the 
same biological pathway, and databases such as PathwayCommons36 can help predict functional consequences 
of such mutated gene sets. Previously derived functional interaction networks37, built from both known and 
predicted protein-protein interactions, can be used to analyse driver gene lists for functional consequences, for 
example, by using GO term enrichment of network modules identified. Additionally, protein-protein interaction 
networks such as STRING38 permit topological predictions, such as whether a particular gene is a hub or how 
dispersed a set of genes are on the network39.
We present a novel study that detects enrichment of cancer mutations in our CATH Functional Families 
(CATH-FunFams)40. CATH v4.0 contains over 25 million domain sequences of known or predicted structure 
classified into 2,735 homologous superfamilies. Within each CATH superfamily, CATH-FunFams comprise evo-
lutionary related domains41 grouped into functionally coherent sets; as such they can help identify functions that 
appear to be targeted in different diseases. Our work builds on earlier studies that used Pfam domains10,17,42,43 to 
detect enrichment, and a recent study that tests enrichment in CATH superfamily domains44. Whilst Pfam fam-
ilies provide high-quality annotation of evolutionary relationships, they may also group related proteins whose 
domains have diverged in function. Recent studies40,45 have shown that CATH-FunFams exhibit higher levels of 
functional purity than either Pfam domains or by using CATH superfamilies. By identifying CATH-FunFams 
enriched with mutations (‘MutFams’) we filter out mutations that do not affect protein function (and thus are 
probably passengers) and as a result identify genes that are more likely to be drivers. In addition, this approach 
reveals functional rather than domain enrichment.
We show that heatmap clustering of cancers by their MutFams provides sensible groupings and that the top 
mutated genes from the MutFams appear to map to a specific set of biological processes as they are significantly 
less dispersed on a protein-protein interaction network compared with sets of randomly chosen genes. Using 
both GO biological process and functional network enrichment of the top mutated genes from all MutFams we 
find convergence on cancer-related processes and pathways. In addition, pathway analysis of a comparable set of 
genes from a related Pfam-based approach10 shows that some of the enriched pathway modules are commonly 
identified by both approaches.
Finally, we performed 3D clustering of all available mutations mapped to representative domain structures 
of the MutFams, followed by detailed proximity analysis of clusters to various functional sites, on the premise 
that mutations from different cancers that cluster near the same sites are likely to be having similar functional 
impacts. We find that, in general, our 3D clustered mutations are closer to functional sites than unfiltered cancer 
mutations.
Our research thus suggests that finding mutation enriched CATH-FunFam domains is a novel and helpful way 
to filter out passenger mutations, and that by selection of the most highly mutated genes in each CATH-FunFam 
we can obtain a broad list of those implicated in cancer. We provide a list of 472 genes identified from our 
MutFams along with a confidence score that can be used to filter for a higher confidence subset of genes. The 
score reflects other evidence supporting a gene’s involvement in cancer: the predicted functional effects; the iden-
tification of cancer-enriched modules on a functional interaction network; significant clustering of mutations on 
protein structures near functional sites and/or agreement with the Cancer Genome Census (CGC) or Pfam based 
gene sets. We find 151 genes (in 98 MutFams) are supported by at least one of these confidence tests, with 79 novel 
genes (in 41 MutFams) not identified, as yet, by the CGC or in the Pfam gene set. The value of our approach is that 
by filtering mutations to enrich for those with functional effects it could help with identification and prioritisation 
of driver genes from large-scale cancer genomics studies.
Results
Mutationally enriched domain functional families (MutFams). We analysed somatic, missense 
mutations from exome/genome-wide studies from 22 cancer types to identify mutationally enriched CATH-
FunFam domain families, which we term MutFams (Fig. 1A and Methods). This step identifies mutationally 
enriched domain families associated with a more specific function than by testing for enrichment at the domain 
superfamily level (either with CATH or Pfam) (Fig. 1B). To assess the value of MutFams for directly compar-
ing diseases, and their functional signatures, we specifically analysed a set of 22 cancers identified in COSMIC. 
We grouped somatic missense mutations from 9,950 whole exome (or genome) samples in COSMIC v71 into 
22 cancer types (based on tumour site, histology and respective subtypes) from which we identified a total of 
259 MutFams (p < 0.05, permutation test with Benjami-Hochberg correction). For a summary of MutFams and 
number of samples by cancer type see Supplementary Table 1. The median number of MutFams per cancer is 
13, ranging from 87 in Skin Cutaneous Melanoma to 2 in Uterine Carcinsarcoma. The number of MutFams per 
cancer does not correlate with sample size, i.e. the number of tumours sequenced (Pearson’s r = 0.232, p = 0.298; 
Supplementary Fig. 1). However, there is a correlation between the number of mutations and the number of 
MutFams identified (Pearson’s r = 0.84, p < 0.0001; Supplementary Fig. 1), an observation supported by a recent 
study reporting a correlation between the overall mutation burden of a cancer type and the number of driver 
genes identified46. We used neutral mutations (polymorphisms) from UniProt as a non-cancer control, resulting 
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in 8 MutFams, with half of these belonging to Class II Major Histo-compatibility Antigens, for which a pool of 
variant alleles is likely to be advantageous47. Supplementary Tables 2 and 3 summarise MutFams for 22 cancers 
and polymorphisms respectively, giving the UniProt functional keywords associated with each.
We used hierarchical clustering of MutFams by cancer, based on shared MutFams, as shown in Fig. 2. In agree-
ment with other domain based methods10,19,48,49 mutations in the tumour suppressor p53 are commonly observed. 
We found 21 out of 22 cancer types have the MutFam ‘Cellular tumor antigen p53′. p53 point mutations are 
observed in many cancers and may be found at multiple sequence positions, but the positions are not generally 
specific to the cancer type50. The second most common MutFam (11 out of 22 cancer types) is the tumour sup-
pressor ‘phosphatase and tensin homolog’ (PTEN), a well-studied regulator of growth factor phospho-inositide 
signalling. Inhibition of PTEN has been shown to suppress regulation of the PIP3 secondary messenger, leading 
to increased growth factor signalling51.
It can be seen in Fig. 2 that cancers from the same primary site (as defined by COSMIC, e.g. lung, large intes-
tine etc) are found to cluster: those of brain tissues, low grade gliomas (LGG), glioblastoma multiforme (GBM) & 
gliomas (GLI); the two main histological subtypes of non-small cell lung cancer, lung adenocarcinoma (LUAD) 
and lung squamous cell carcinoma (LUSC) and the colorectal subtypes of colon adenocarcinoma (COAD) and 
rectal adenocarcinoma (READ). The large number of skin cutaneous melanoma (SKCM) MutFams (87) may be 
due to skin exposure to external carcinogens and is consistent with the highest mutation burden being observed 
in melanomas in general52. Additionally, thyroid carcinoma (THCA) is seen to cluster with the polymorphic data-
set, being the only cancer not to have the p53 enriched MutFam. p53 is known to be affected in THCA via other 
mutation types (i.e. not missense) such as truncations, or by mutations occurring in regulatory transcription fac-
tors53. Additionally, while there are some MutFams common to all cancers, as discussed above, many are distinct 
(i.e. tissue-specific) and found uniquely within particular cancers, such as Skin Cutaneous Melanoma (SKCM), 
Acute Myeloid Leukemia (LAML), Bladder Cancer (BLCA), Liver hepatocellular carcinoma (LIHC) and Kidney 
renal clear cell carcinoma (KIRC) (as indicated in Fig. 2; for specific MutFams see Supplementary Table 2).
Comparison of MutFam genes with those identified by other approaches. We compared genes 
from MutFams with a subset of cancer implicated genes from the Wellcome-Sanger Cancer Gene Census (CGC)54 
containing somatic missense mutations known to be associated with cancer. We also compared with another 
comprehensive set of genes identified using a related Pfam-based approach by Miller et al.10 (see Methods for 
description of Miller set). MutFam genes are significantly enriched in CGC-curated cancer driver genes, with the 
49 in common representing 21% of CGC genes ( < −p 10 15, Fisher’s). We compared this enrichment with that 
observed for the gene list identified by the related Pfam based approach by Miller et al.10 (see Methods). The 
Figure 1. CATH-FunFams form the basis of our mutation analysis pipeline and are central to the workflow 
used in this analysis of cancer mutations (A). CATH-Superfamilies, or equivalent Pfam families, may include 
sequences with diverse functions (B, top). FunFams subdivide families into more functionally specific sets of 
sequences (B, bottom) allowing detection of mutation enrichment specific to FunFam1 that is not significant 
when mutations in FunFam1 and FunFam2 are aggregated at the family level.
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Miller set is also significantly enriched in CGC drivers with 30 genes in common representing 13% of the Miller 
dataset ( < −p 10 15, Fisher’s). Prior to any further filtering of these gene sets, each method identifies a majority of 
genes uniquely (Fig. 3). We find 41 genes in common between the MutFam and Miller sets. Whilst this is a rela-
tively low overlap between the genes identified by the MutFam and Miller sets, a recent study by Tokheim et al.55, 
which investigated overlap between driver genes predicted by 8 different methods, also showed that overlap of 
genes from individual methods with CGC was low. They did however find that the union of drivers from all meth-
ods showed significant enrichment of CGC genes. To investigate whether the unique genes in our dataset could 
be validated by other approaches, we examined their proximity in protein networks and also looked for associa-
tion in biological pathways.
Figure 2. Heatmap shows overall diversity of functions affected in different cancers and clustering of certain 
cancers by primary tumour site. Each horizontal bar represents a MutFam, with enrichment factors shown using 
colour intensity. MutFams that include tumour suppressor genes TP53 and PTEN are shared amongst the largest 
number of cancers. Tumours from the same primary site that cluster by their MutFams are shown in more 
detail for gliomas (top right) and colorectal cancers (bottom right) and include the CATH Functional Family 
names. For gliomas, MutFams include genes TP53, PTEN and CHEK2 found in all three subtypes (LGG, GBM 
and GLI), with genes such as EGFR and ZNF429 found only in GLI and late stage GBM. For colorectal cancers, 
common MutFams include TP53, PTEN, KRAS, PIK3CA and the F-box/WE repeat containing FBXW7, with 
COAD containing many unique MutFams including genes EGFR, NRAS and relaxin receptor 2 (TSHR). 
(A) full list of MutFams in given in Supplementary Table 2. BLCA Bladder cancer; BRCA Breast invasive 
carcinoma; COAD Colon adenocarcinoma; DLBC Lymphoid Neoplasm Diffuse Large B-cell Lymphoma; ESCA 
Esophageal carcinoma; GBM Glioblastoma multiforme; GLI Gliomas; KIRC Kidney renal clear cell carcinoma; 
LAML Acute Myeloid Leukemia; LGG Low grade gliomas; LIHC Liver hepatocellular carcinoma; LUAD Lung 
adenocarcinoma; LUSC Lung squamous cell carcinoma; OV Ovarian serous cystadenocarcinoma; PAAD 
Pancreatic adenocarcinoma; PRAD Prostate adenocarcinoma; READ Rectum adenocarcinoma; SKCM Skin 
Cutaneous Melanoma; STAD Stomach adenocarcinoma; THCA Thyroid carcinoma; UCEC Uterine Corpus 
Endometrial Carcinoma; UCS Uterine Carcinosarcoma; POLY Polymorhisms (neutral mutations).
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MutFam genes are less dispersed than random on a protein-protein interaction network. Prior 
to any further filtering and enrichment of the top mutated genes from the MutFams, we analysed their overall 
dispersion on a comprehensive protein-protein interaction network using DS-Score, a measure adapted from 
Menche et al.39 (see Methods). MutFam genes were significantly closer (less dispersed) on the network compared 
to randomly selected sets of genes (DS-Score 1.212, < . × −p 1 2 10 13, Mann-Whitney test). Similarly, the set of 
genes from Miller also showed lower dispersion compared to random (DS-Score 1.463, = . × −p 1 0 10 8, 
Mann-Whitney test) (Supplementary Table 4). These lower dispersion scores indicate that the tested genes are on 
average more closely connected in the network and thus more likely to be involved in the same biological 
processes.
Enrichment of MutFam and Miller genes in common pathway modules and processes associ-
ated with cancer. We tested enrichment of the uniquely identified MutFam genes to identify whether they 
affected specific biological processes or were convergent on the same (or closely related) processes mediated 
by unique genes from the Miller set. We used two approaches for each of the MutFam and Miller gene sets: (1) 
GO-Slim term enrichment and (2) GO Biological Process (GO-BP) enrichment of functional interaction network 
modules.
GO-Slim term enrichment. The 420 unique top mutated genes from the MutFams show enrichment in 16 
GO-Slim terms, which we manually categorised into 5 cellular event categories: “embryonic development”, “cell 
migration”, “differentiation”, “stress response” and “cell signalling and transport” (Fig. 4). The 224 Miller genes 
were enriched in 27 GO-Slim terms in 6 cellular event categories (Supplementary Fig. 2). Despite differences 
between the specific GO-Slim terms found in each gene set, 3 of the cellular event categories were common to 
both MutFam and Miller (“embryonic development”, “cell migration” and “cell signalling and transport”) and 
each of these categories also contained at least one specific GO-Slim term common to both gene sets. The 12 
common genes (between MutFam, Miller and CGC) were enriched in three GO-Slim terms involved in cell sig-
nalling and transport, including the immune related signalling term “I-KappaB Kinase/NF-KappaB cascade” and 
“receptor-mediated endocytosis” (Supplementary Fig. 2). From this broad overview of the functional attributes 
of MutFam genes, we characterised specific processes in greater detail.
GO Biological Process enrichment of functional interaction network modules. Functionally 
related groups of genes were identified, for both the 12 common genes (“common”) and the genes unique to each 
of the datasets (“MutFam unique” etc.), by mapping each set to a pathway-based functional interaction network 
(Reactome FI, derived by Wu et al.56), clustering these networks into modules and then calculating GO BP term 
enrichment for every module. We mapped 193 out of 420 (46%) unique MutFam genes, 119 out of 224 (53%) 
Miller genes, and 9 out of 12 (75%) common genes to the functional network. Not all genes map to functional 
modules because they lack any functional associations with other proteins in the network. Overall, 2 (out of 2) of 
the network modules for common genes, 12 (out of 21) modules for MutFams and 5 (out of 7) modules for Miller, 
showed enrichment for at least 1 GO BP term (FDR < 0.001).
The genes commonly identified by MutFam, Miller and CGC were enriched in receptor signalling processes 
and downstream kinase signalling pathways (see Supplementary Section 1.1). We found that genes uniquely 
Figure 3. MutFam genes are significantly enriched in CGC genes. The Pfam-based method (Miller) is also 
enriched in CGC genes and both methods predict distinct drivers.
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identified by each method show different degrees of convergence at the functional module level. Such conver-
gence may be very specific; a functional module identified from MutFam genes was associated with NOTCH 
signalling via NOTCH genes, whereas a module in Miller identified upstream and downstream regulators of the 
same pathway. Unique MutFam and Miller genes also converged on broader but clearly related biological pro-
cesses of transcriptional regulation via proteins containing zinc finger domains. Finally, functional convergence 
was identified via broad and less specific pathways relating to cellular development (for further details on conver-
gence between the unique MutFam and Miller genes see Supplementary Section 1.1).
Overall, our analysis of the genes identified by MutFam and Miller show that whilst there are only a modest 
number of genes commonly identified by both methods, at the level of biological processes and pathways there 
is much better agreement. Of the 193 MutFam genes mapped to the functional network, 168 were in enriched 
modules (~85%). For at least 40% of these genes (68 genes) there was some other information supporting a cancer 
association i.e. literature, presence in a biological process in common with Miller or a link to cancer hallmarks 
(See Supplementary Sections 1.1–1.3). Thus, by identifying different genes involved in common cancer-related 
pathways and by highlighting additional cancer-associated processes, the MutFam and Miller approaches can be 
considered broadly complementary.
Our pathway analysis further validates our MutFam selection, by revealing significant enrichment of MutFam 
genes in cancer-associated modules, and helps identify a more confident set of putative driver genes i.e. that are 
found both in mutationally enriched MutFams and enriched functional modules.
Detailed analysis of MutFam driver genes in brain cancers. In addition to the comprehensive 
analyses of MutFam mutated genes above, two specific cancers were subjected to more detailed analyses using 
Reactome Pathways and Gene Ontology (GO) enrichment: low-grade glioma (LGG) and glioblastoma multi-
forme (GBM). We found that processes enriched in GBM are consistent with it being a later stage (and more 
aggressive) glioma and include chaperone functions in proteostasis and immune functions. For a full summary 
see Supplementary Section 1.4.
Identifying mutationally enriched 3D clusters in representative domain structures of MutFams. 
We used functionally pure CATH-FunFams to detect domain families (MutFams) enriched in cancer disease 
mutations. To detect whether mutations within these MutFams were enriched in particular 3D locations we 
mapped the mutations onto a representative 3D structure for each family (Fig. 1). Previous studies have shown 
considerable structural coherence within CATH-FunFams40,45. We used an in-house method (see Methods), to 
identify residues that have significantly more neighbouring mutations (i.e. within 5Å) than would be expected 
by chance. Therefore, by seeking evidence of 3D clustering of mutations from MutFam genes we are able to 
filter out passenger mutations and identify a subset of putative driver genes and driver mutations with higher 
confidence to be associated with one or more cancers. We identified 175 clusters in 42 genes, comprising a total 
of 970 single point mutations. Since our hypothesis was that mutations clustering in 3D are more likely to be 
affecting functional sites in the protein, we assessed the value of these clusters for identifying putative drivers by 
their proximity to known and predicted functional sites in proteins. An example of a MutFam cluster occurring 
near functional sites in CHEK2 (Serine/threonine kinase Chk2) is shown in Fig. 5. CHEK2 is an essential regu-
lator of genome integrity and becomes activated in response to double-stranded DNA damage. This activation 
Figure 4. Genes uniquely identified from MutFams are enriched in 16 GO-Slim terms representing five main 
cellular processes. GO-Slim terms in common with Miller are shown in bold.
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leads to phosphorylation and inhibition of downstream targets involved in cell cycle progression, leading to cell 
cycle arrest57. We observe mutations in CHEK2 clustering near the ATP binding pocket (centred on residue 
355) and in the activation loop (centred around residues 392, 394 and 396), functional sites critical for CHEK2 
kinase activity. Mutations affecting CHEK2 kinase activity could drive tumourigenesis by preventing inhibition 
of cell-cycle progression in response to DNA damage thus leading to genome instability. Additionally, both apop-
tosis and genome repair processes could be inhibited via downstream CHEK2 signalling58. The MutFam contain-
ing CHEK2 “Calcium/calmodulin-dependent protein kinase type II delta 2 chain” is identified in glioblastomas 
(Supplementary Table 2 and Section 1.4) and lung adenocarcinomas (Supplementary Table 2). CHEK2 is iden-
tified in the CGC from frameshift germline mutations (i.e. not somatic missense mutations) and annotated as 
a tumour suppressor whereby frameshifts variants lead to increased risk of familial breast cancer. Clustering of 
cancer mutations near key functional sites is further illustrated for the extra-cellular dimerization interface of 
EGFR and for the BRAF kinase domain in Supplementary Fig. 3.
Proximity of MutFam cluster mutations to functional sites. We calculated proximity distributions 
of mutations to catalytic residues, protein-protein interface sites (PPI), ligand-binding and FunSites (highly con-
served residue sites in CATH-FunFams, see Methods). Distance distributions of mutations to each of these site 
types were calculated for the MutFam cluster mutations and for an unfiltered set of mutations from COSMIC (see 
Methods). Mutations in oncogenes and TSGs were examined separately to see if oncogene mutations were more 
likely to be near functional sites. As mentioned above, since the protocol used to find the enriched clusters is 
designed to filter out noise by excluding passenger mutations, we expected mutations in these clusters to be closer, 
in general, to functional sites than mutations in unfiltered datasets. All were compared to the control distribution 
derived from UniProt neutral mutations, which were further filtered by excluding heavily mutated proteins (>50 
mutations) to avoid bias. Distances of mutations to functional sites are shown as empirical cumulative density 
functions for each functional site type.
Catalytic sites. The mutations in oncogenes from the unfiltered pan-cancer set tend to be closer to catalytic residues 
than neutral mutations, though not significantly ( = . < .OR p1 72, 0 054, Fisher’s exact test), while TSGs show an 
equivalent but significant tendency ( = . < .OR p1 72, 0 0044). However, MutFam clustered mutations do show a 
much more significant tendency to be closer to catalytic residues ( = . < . × −OR p2 98, 3 4 10 15) (see Fig. 6).
Protein-protein interaction sites. Protein interfaces can cover large areas on the surface of the protein, thus sub-
stantial proportions of both cancer and neutral mutations are close to interfaces (Fig. 6). Unfiltered cancer muta-
tions in both oncogenes and TSGs show significantly higher propensities to lie close to interfaces (as defined by 
Figure 5. Mutations in CHEK2 cluster near specific functional sites. CHEK2 is a checkpoint kinase regulating 
genome integrity by arresting cell-cycle progression following DNA damage. The phosphotransferase domain 
shown is representative of a MutFam identified in gliomas and glioblastoma “Calcium/calmodulin-dependent 
protein kinase type II” [PDB ID: 2ycf]. Mutation clusters A and B (red) are within 5Å of both known and 
predicted functional sites (FunSites). Cluster A (centred on residue 355) is close to the ATP binding pocket, for 
which Catalytic Site Atlas (CSA) residues are highlighted green. Cluster B (centred around residues 392, 394 
and 396) is in the activation loop near the APE motif, involved in kinase activation, which involves transient 
CHEK2 dimerization and autophosphorylation. Further CSA residues near cluster B are highlighted green. 
Clustering of cancer mutations near catalytic residues imply a reduction of CHEK2 kinase activity, preventing it 
from inhibiting cell-cycle progression in response to DNA damage and helping to drive tumourigenesis.
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IBIS) than neutral mutations (oncogenes = . < . × −OR p1 71, 3 6 10 13; TSGs = . < . × −OR p1 71, 4 7 10 15, 
Fisher’s exact test). As with catalytic sites, the tendency is more pronounced for the MutFam mutations filtered by 
3D clustering = . < . × −OR p( 2 52, 2 3 10 16).
Ligand-binding sites. Mutations in oncogenes show a small, significant enrichment near ligand binding sites 
( = . < . × −OR p1 46, 9 4 10 8, Fisher’s exact test), but those in TSGs are not significantly different to neutral 
( = . < .OR p1 1, 0 23). However, MutFam clustered mutations are significantly closer to ligand-binding sites than 
neutral = . < . × −OR p( 1 78, 2 3 10 16) (Fig. 6).
Predicted functional sites (FunSites). Predicted FunSites (highly conserved residues in multiple sequence align-
ments of FunFam relatives) have been shown to be enriched in both catalytic and protein interface residues59. 
Therefore, it is not surprising that we see similar trends to those observed for these types of residues (i.e. CSA and 
IBIS interface) (Fig. 6). In addition, FunSites are likely to include other sites important for the stability, folding 
and any allosteric mechanisms. Both oncogenes and our clustered MutFam mutations show a high propensity to 
lie close to these sites (oncogenes = . < . × −OR p2 45, 3 6 10 11; MutFam clusters = . < . × −OR p84 7, 2 3 10 16, 
Fisher’s Exact test), with, again, the filtered MutFam mutations showing a more significant tendency. This is con-
sistent with studies that show that somatic cancer disease mutations occur close to conserved sites17,60. This result 
reinforces the validity of our 3D clustering strategy to remove noise and identify driver mutations. Furthermore, 
using our functionally pure CATH-FunFams to detect structurally and functionally significant sites through con-
servation analyses helps to reveal the functional significance of these mutations.
Scoring MutFam genes using evidence of functional impacts suggests putative drivers. A set 
of 472 genes was initially identified by selecting the top mutated genes from each of the CATH-FunFams enriched 
in mutations (see Methods). This aggregation of mutations in sets of domains having related functions provides 
some evidence for likely impact on protein function. To filter this set further and obtain a set of putative driver 
genes we used multiple lines of evidence by identifying: (1) genes in common with those predicted using the 
Miller method; (2) genes in common with CGC; (3) genes in cancer-related GO functional modules (as discussed 
above, with further details in Supplementary Sections 1.1–1.3 and Methods) and (4) genes from MutFams con-
taining a 3D cluster near a functional site. By using these multiple sources of evidence for the functional impact 
of putative MutFam driver genes in cancer we can identify a set of 151 more confidently predicted driver genes 
that are predicted from MutFams and have at least one of the other four pieces of supporting evidence outlined 
above. For a full list of all 472 MutFam genes and the associated confidence scores, see Supplementary Table 11. 
Figure 6. Proximity distributions show that 3D clustered cancer mutations are closer to functional sites than 
unfiltered mutations. For known functional sites (CSA, Ligand or PPI) 3D clustered mutations are closer 
than unfiltered mutations from either oncogenes or TSGs. For highly conserved residues in FunFam multiple 
sequence alignments highly enriched in known functional sites (FunSites), clustered mutations are significantly 
closer than unfiltered oncogene cancer mutations (there were too few distances measured to plot distributions 
for FunSites/TSGs). All distributions use UniProt neutral as a control.
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A summary of the 151 MutFam driver genes is provided in Table 1, with each gene categorised by general protein 
function and the cancer types in which the gene was identified.
Since comparing the number of putative driver genes in MutFams with the list of CGC genes containing 
missense mutations (downloaded September 2016), additional cancer driver genes have been added to CGC. 
This increases the set of genes common to both CGC and MutFam by 11 genes (CNTNAP2, DCC, EPHA7, 
FKBP9, ISX, PIK3CB, PREX2, PTPRT, TNC, ZNF429, ZNF479) (CGC 5th Feb 2018 download) and increases 
the overall percentage of MutFam genes in CGC from 21.1% to 25.9%. One of these was also identified in the 
Miller set (PIK3CB). Of the 11 genes, three (PIK3CB, PREX2 and PTPRT) are in the new “Tier 1” category 
(there are 2 tiers), defined by the CGC as those with the strongest evidence for a role in cancer. We had identified 
EPHA7 in our set of putative drivers filtered to include genes having both pathway enrichment and 3D clustering 
(see Supplementary Table 11). Although having only 2 mutations within the FunFam boundaries of the gene 
EPHA7 itself, the MutFam (Ephrin type-B receptor 2) was found to be enriched based on 12 mutations found in 
Ovarian cancer across 8 genes within the FunFam. Five of these genes only contributed a single mutation each 
to the MutFam. Calling EPHA7 a predicted driver gene on the basis of these numbers would be dubious, but by 
combining other types of evidence for functional effects the case is stronger. By using the total set of pan-cancer 
mutations, a total of 46 mutations in this FunFam gave a significant cluster in 3D that was near a predicted func-
tional site. Additionally, GO process enrichment identified EPHA7 as part of enriched processes in cellular devel-
opment. Other putative drivers highlighted in Table 1 but not in CGC or Miller are in the MutFam “Hepatocyte 
growth factor receptor”. The genes PLXNA1, PLXNA2 and PLXNA4 are enriched in cellular development - axon 
guidance processes and 68 pan-cancer mutations show a significant clustering of mutations, near a predicted 
functional site (i.e. based on the most highly conserved positions within the FunFam) and an IBIS PPI site. A 
recent study indicates role for PLXNA161 in pancreatic cancer cell lines in enhancing tumour proliferation and 
General Function Genes Cancers
Apoptosis BCL6 DLBC
Chromatin SWI/SNF complex ATRX, SMARCA4 GLI, PAAD
Chromatin other CTCF UCEC
Genome integrity TP53, CHEK2
BLCA, BRCA, COAD, DLBC, ESCA, 
GBM, GLI, KIRC, LAML, LGG, LIHC, 
LUAD, LUSC, OV, PAAD, PRAD, READ, 
SKCM, STAD, UCEC, UCS
MAPK signalling BRAF, DUSP1, DUSP10, DUSP5, DUSP6, DUSP7, DUSP19
COAD, GLI, LGG, LUAD, READ, SKCM, 
THCA
Metabolism IDH1, IDH2, MYH4, PGM5, POLE GLI, LAML, LGG, SKCM, STAD, UCEC
NFKB signalling MYD88 DLBC
NOTCH signalling NOTCH1, NOTCH2, NOTCH4 GLI, LGG, LUAD
PI3K signalling AKT1, PIK3CA, PIK3CB, PIK3R1, PTEN
BLCA, BRCA, COAD, ESCA, GBM, GLI, 
KIRC, LGG, LIHC, LUAD, LUSC, READ, 
SKCM, UCEC
RTK signalling BMPR1A, EGFR, ERBB2, FGFR2, FLT3, KDR, KIT, MET, RET, BMPR2, EPHA7, EPHB1, EPHB3
BLCA, BRCA, COAD, GBM, GLI, 
LAML, LUAD, OV, SKCM
TGFB signalling CBL, SMAD4, TGFBR2, ARHGEF18 COAD, ESCA, PAAD, READ, SKCM, STAD
TOR signalling STK11 LUAD
Signalling including RAS
CDH1, FAT4, HRAS, KRAS, NRAS, PTPN11, RAC1, 
RAP2C, TSHR, CDH5, DCC, GRIK1, GRIK2, GRIK4, 
HLA-DQB1, ITSN1, KALRN, NET1, NGEF, OBSCN, 
PLEC, PLXNA1, PLXNA2, PLXNA4, RALA, RIT2, 
ROBO1, UNC5C, UNC5D, VAV2
BLCA, BRCA, COAD, KIRC, LAML, 
LIHC, LUAD, PAAD, READ, SKCM, 
STAD, THCA, UCEC
Cadherins
PCDHA7, PCDHA10, PCDHA11, PCDHB11, 
PCDHB15, PCDHB4, PCDHB5, PCDHB6, 
PCDHB7, PCDHGA12, PCDHA1, PCDHA13, 
PCDHA2, PCDHA3, PCDHA4, PCDHA5, PCDHB10, 
PCDHB12, PCDHB14, PCDHB16, PCDHB2, PCDHB3, 
PCDHGA1, PCDHGA2, PCDHGA3, PCDHGA6, 
PCDHA6, PCDHA8, PCDHA9, PCDHB13, PCDHB8
BLCA, BRCA, COAD, ESCA, GLI, 
LAML, LIHC, LUAD, LUSC, OV, PRAD, 
READ, SKCM, STAD, THCA
Protein homeostasis/ubiquitination BAP1, FBXW7, SPOP, VHL BLCA, COAD, KIRC, LUSC, PRAD, READ, SKCM, STAD, UCEC, UCS
Splicing SF3B1 BRCA, PAAD
Transcription factors
CIC, EZH2, FOXA1, FOXJ1, FOXK1, FOXK2, FOXL2, 
HIF1A, LZTR1, WT1, ZNF107, ZNF189, ZNF333, 
ZNF560, CELSR2, DUSP22, ZNF100, ZNF138, ZNF267, 
ZNF429, ZNF43, ZNF430, ZNF431, ZNF479, ZNF492, 
ZNF506, ZNF585A, ZNF585B, ZNF676, ZNF708, 
ZNF714, ZNF83, ZNF98
BLCA, BRCA, COAD, DLBC, GBM, 
GLI, LGG, LIHC, LUSC, READ, SKCM, 
THCA, UCEC
Other CSMD1, SEC. 24 C, DSP, EPPK1, SSH1, SSH3, TTN BLCA, COAD, LIHC, LUAD, READ, SKCM, THCA
Table 1. Summary of protein functions and cancers for the top mutated MutFam genes having some other 
supporting evidence. Genes in bold were also identified in either CGC or Miller.
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invasion. Genes in Table classified as “Other” have been further checked to ensure these do not include false pos-
itive identifications, as discussed in Supplementary Section 1.5.
A full list of 472 genes in all identified MutFams is provided, along with the supporting evidence and overall 
score in Supplementary Table 11.
Discussion
We have exploited a set of domain functional families (CATH-FunFams) classified within CATH domain struc-
ture superfamilies. Relatives in these families are clustered on the basis of structural and functional similarity. 
Structural coherence has been validated by structural superposition of relatives with known structures in the 
PDB, whilst functional purity is reflected in the performance of the families for providing functional annotations 
for uncharacterised relatives40,62 and in the fact that highly conserved residue sites within the family are enriched 
in known functional sites residues including catalytic and ligand binding residues40.
Previous studies demonstrated the value of looking for mutationally enriched regions within proteins on 
the premise that mutations in these regions could convey functional effects driving cancer. Whilst most studies 
exploited Pfam families, here we examined the benefits of using families explicitly clustered on functional similar-
ity. We identify 259 mutationally enriched families (MutFams) and observe that diseases can be clustered in a sen-
sible manner on the basis of their MutFams, with diseases affecting similar tissues (e.g. gliomas) clustering closely 
on the basis of shared MutFams. The lack of any correlation between the sample size (number of tumours) and 
the number of MutFams identified indicates that comparisons between cancer types are not confounded by the 
different numbers of tumours analysed in each, and we would expect further samples to increase the enrichment 
factor of existing MutFams, and (to a lesser extent) highlight a few new MutFams that pass over the significance 
threshold. There is a correlation with the number of mutations per cancer type and the number of MutFams, sug-
gesting that cancers with high mutational burden, due to exposure to external mutagens (such as skin, lung and 
colorectal cancers), have a larger pool of mutations from which tumour evolution can select a more diverse range 
of functional mutations than cancers having a lower mutational burden.
Despite differences in the driver genes identified by other independent methods (e.g. the Miller dataset) and 
CGC there is substantial convergence of MutFam driver genes at the level of GO biological processes affected, as 
also shown in Baudot et al.63. Broadly, MutFams are complementary to Pfam-based methods.
The lower overall dispersion of MutFam genes on a PPI network compared to random implied that the genes 
were closer together on the network and therefore likely to be in related processes. This suggested that a more 
detailed analysis using a pathway-derived functional network would help in identifying enriched functional 
modules. Literature analysis of these enriched modules revealed biological processes known or highly likely to 
be involved in cancer and showed that the MutFam and Miller gene sets tend to converge on similar biological 
processes despite relatively low overlap of the actual gene sets. Furthermore, the cancer sets identified by the 
MutFam and Miller methods were found to be biased towards different tissues, and the genes therefore operating 
in different cellular contexts, which may partly explain this low overlap.
Finally, we also looked at the proximity of mutation clusters to functional sites, where available, to provide 
additional evidence for a gene’s functional relevance.
Our results suggest that our FunFam protocol is complementary to a Pfam based approach. Pfam families are 
larger and less specific than CATH Functional Families with a broader sampling of biological sequence space, 
and analyses have shown greater functional divergence within Pfam families than FunFams40. This divergence 
may lead to some drivers being missed as functionally diverse relatives in the family may have no or few muta-
tions (as illustrated in Fig. 1B). By contrast the smaller size of FunFams may mean that enrichment values fall 
below the threshold, again causing driver genes to be missed. However, the higher number of genes identified 
by our MutFam analysis (i.e. 472 compared to 271 for the Miller set) suggests that the higher functional coher-
ence of our families is helpful in detecting mutationally enriched families. For example, our MutFam approach 
detects EPHA7, which is not picked up in the Miller set, but was confirmed by a later release of the CGC. It is 
also reassuring that a high percentage of MutFam genes, mapped to the functional network, are in enriched 
modules. Furthermore, functional coherence of FunFams, and their associated structural coherence40, facilitates 
more accurate multiple sequence alignments which in turn facilitates more accurate prediction of functional sites, 
based on highly conserved positions within the FunFam. The functional site data, combined with available rep-
resentative structures from FunFams, allow identification of mutations occurring (or clustering) near the known 
characterised functional sites or predicted functional sites. Since there are relatively few experimentally char-
acterised functional sites, CATH-FunFams therefore bring significant benefits from the larger set of predicted 
functional sites they provide. Thus, the use of representative structures from MutFams provides an effective filter 
for identifying mutations near functional sites that are likely to have specific functional effects.
In support of a combined MutFam and Pfam approach, Pfam includes domain families for which no struc-
ture is available and families for which there is no experimental characterisation of function (e.g. Domains of 
Unknown Function - DUFS), which are not currently represented in CATH-FunFams. Other non-structural 
regions, such as protein N and C termini, may have cancer-associated mutations but are not included in our 
analyses if they lie outside the domain.
The complete list of 472 genes identified from MutFams is provided (Supplementary Table 11). By focussing 
on mutations that affect function i.e. by enrichment in CATH-FunFams, in biological processes linked to cancer, 
or in clusters near functional sites, we provide a novel protocol for filtering out passengers and predicting putative 
driver genes. In total, 151 genes are suggested by our MutFam method having biological process enrichment, 3D 
clustering or agreement with other datasets. A recent large-scale study by Bailey et al.46 used a consensus scoring 
approach combining predictions from 26 software tools to identify 299 cancer driver genes. This set of 299 genes 
represents the most up-to-date consensus of drivers we had at the time of submitting this manuscript. Overall, 
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a comparable 11% of 472 MutFam genes and 14% of 271 Miller genes are found in the consensus 299-gene set. 
However, 29% of the 151 MutFam gene set, i.e. those genes having evidence of functional effects, are in the con-
sensus set, illustrating the value of our approach in filtering putative driver gene sets this way.
MutFams identified 79 genes uniquely that are not found in CGC or Miller, but have evidence for a functional 
role via biological process enrichment or 3D clustering. These could aid prioritisation of functional studies of 
putative novel driver genes identified from large-scale cancer genomics studies.
Methods
Datasets and sources. CATH Functional families. We used CATH-FunFams from version 4.0 of the 
CATH database41, which classifies 235,000 structural and over 25 million predicted domain sequences into 2,735 
homologous superfamilies, which are then sub-divided into 110,439 functional families (CATH-FunFams).
CATH-FunFams are sets of evolutionary related domains clustered into families on the basis of predicted 
structural and functional similarity. CATH-FunFams are identified using agglomerative clustering of domain 
sequences within a CATH-Gene3D superfamily, and entropy based analyses to distinguish CATH-FunFams hav-
ing distinct specificity determining residues40. CATH-Gene3D comprises all sequences from UniProt, which 
are known or predicted to belong to CATH domain structure superfamilies. CATH-FunFams have been highly 
ranked by the Critical Assessment of Functional Annotation (CAFA62) and shown to be more functionally coher-
ent than Pfam families40. Typically, several CATH-FunFams map to a Pfam family. In other words, although Pfam 
has been frequently used to increase the power of driver gene detection by accumulating mutation information 
across relatives within a Pfam family, this is also likely to introduce noise as Pfam families are not specifically 
classified for functional coherence and can contain relatives with rather diverse functions. Mutations in these 
domains may be exerting different effects as the genes may be operating in different pathway or cellular contexts 
and comprise different protein interfaces or active site residues. Previous studies comparing Pfam and CATH 
functional families for enzymes, showed that approximately 50% of Pfam families comprised more than one 
enzyme class (i.e. as reported by the enzyme classification) whilst less than 15% of CATH-FunFams comprised 
more than one enzyme class40.
For example, to illustrate the benefits of the CATH functional sub-classification, the schematic illustration 
in Fig. 1B shows that analysis of the broad Pfam family shows no significant enrichment of mutations as some 
relatives have none or few mutations (for example, because these are paralogous relatives that operate in a dif-
ferent cellular context and hence lack the protein interface containing mutated residues found in the other rel-
atives). Separating these relatives into distinct CATH-FunFams enables detection of mutational enrichment 
in CATH-FunFams. Conversely, the finer splitting of CATH superfamilies into FunFams may result in some 
CATH-FunFams being too small to detect mutation enrichment. It is therefore reasonable to suppose that muta-
tion analysis by CATH-FunFams yields complementary driver gene lists to those obtained by related studies using 
Pfam families (e.g. by Miller).
Because of their functional purity, conserved residues within CATH-FunFams have been found to be 
enriched in known functional sites e.g. catalytic residues in CSA25. They have also been shown to be structurally 
coherent59,64. Highly conserved sites within CATH-FunFams (also described as FunSites) are found by analys-
ing sequence conservation in a multiple sequence alignment of the FunFam, using the scorecons algorithm65. 
Scorecons conserved sites can only be reliably identified for CATH-FunFams having high information content 
(i.e. sequence diverse relatives) as measured by the DOPS score returned by scorecons. FunSite data was only 
generated for CATH-FunFams having a DOPS score ≥ 70 (range 0 to 100).
Cancer, polymorphism and disease datasets. Cancer datasets: 22 cancer-specific datasets were generated com-
prising somatic, non-synonymous missense exonic mutations from COSMIC66 v71, using variants from whole 
exome/genome studies, then filtering for each cancer type using tumour site and histology data with TCGA-style 
classes to define cancer types (summarised in Supplementary Table 1). Cancer datasets are used to define 
MutFams (see section “Calculation of MutFams - CATH-FunFams enriched in cancer mutations” below).
UniProt neutral/polymorphism dataset: 8,838 neutral mutations were obtained from 1,926 proteins using 
UniProt Humsavar33 (March 2014) by selecting entries annotated as “polymorphism”. This UniProt neutral data-
set is used as a neutral control for the cancer datasets.
Pan-cancer dataset: 800,704 somatic, non-synonymous missense exonic variants from whole genome/exome 
studies from COSMIC v71 with no filtering by tumour site or histology. Note that the pan-cancer dataset is 
larger than all of the 22 cancer datasets combined as it includes many cancer sub-types from COSMIC that have 
few patient samples. This set is used to give as large and comprehensive cancer mutation dataset to use for 3D 
clustering as possible, based on the hypothesis that mutations from different cancers that cluster near the same 
functional site are likely to act via similar functional impacts. Subsets of the pan-cancer dataset were defined 
as “COSMIC oncogenes” and “COSMIC tumour suppressors” using gene roles identified by Wellcome-Sanger 
Cancer Gene Census (CGC)54. These sets allow for independent testing of the proximity of mutations to func-
tional sites to account for any differences in the distribution of mutations found between oncogenes and TSGs.
PDB structures. Mutations were mapped to PDB structures using data in CATH v4.0 imported via SIFTS. 
Where multiple structures existed for a given UniProt protein, a single PDB was selected by selecting for maxi-
mum mapped sequence length followed by highest resolution, as per Stehr et al.6. Overall, we were able to map 
1,893 COSMIC oncogene, 3,184 COSMIC TSG and 8,838 UniProt neutral mutations to structures.
Functional sites. Functional sites were classified using catalytic residues from Catalytic Site Atlas 2.0 (CSA)25 
and both protein-protein interaction (PPI) and ligand binding sites from NCBI-IBIS67. We additionally included 
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ligand sites from ccPDB68 by filtering using their scoring metric (using AUC > 0.8 and MCC > 0.3) to include 
ligands ADP, ATP, FAD, FMN, GDP, HEM, NAD and PLP. We also analysed proximity to highly conserved sites 
(FunSites) within CATH-FunFams40. As previously described, FunSites are found using the scorecons algo-
rithm65 for CATH-FunFams having high information content (i.e. sequence diverse relatives) as measured using 
the DOPS score returned by scorecons. FunSite data was only generated for CATH-FunFams having DOPS 
score ≥ 70 (range 0 to 100).
Calculation of MutFams - CATH-FunFams enriched in cancer mutations. For each of the cancer datasets 
(pan-cancer plus 22 cancer-specific) and UniProt neutral, we identified ‘MutFams’ as CATH FunFam domains 
significantly enriched in mutations. This protocol is based on Miller et al.10 and outlined below.









where ef is the enrichment score of mutations (for a given database such as COSMIC) occurring in FunFam f; mf 
is the observed number of mutations occurring in FunFam f; me is the expected number of mutations in FunFam 
f, calculated as total number of mutations observed in all genes containing the FunFam, ng, and the fraction of 
amino acids, fm, within CATH-FunFams compared to the total number in genes. Enrichment score significance 
was assessed using a permutation test as follows:
For each FunFam f:
Get the set of human genes containing the FunFam domain
For each permutation i (1 to 10000):
For each gene, g, count the number of mutations ng; randomly distribute the ng mutations across gene g, allow-
ing multiple mutations per amino acid.
Calculate mi, the total mutations for iteration i that are within the FunFam boundaries of the genes.
Enrichment p-value is defined as proportion of iterations where mi ≥ mf, where mf is the observed mutation 
count for FunFam f.
For each disease type, MutFams were filtered to avoid noisy results from singleton mutations or very low 
counts by excluding those where total mutation count ≤ 10 (within FunFam boundaries, across all human 
genes and for multiple-spanning discontinuous sequence ranges, if applicable). Additionally, MutFams 
with enrichment factor ef ≤ 1 were removed, as these are - by definition - not enriched. For example, out of 
the 3,124 CATH-FunFams in GBM (glioblastoma multiforme) with at least one mutation, 45 remain follow-
ing the process and filtering outlined above. For each cancer type we applied Benjami-Hochberg (BH) correc-
tion to the permutation-derived p-values to correct for multiple testing of the mutation data set across multiple 
CATH-FunFams (applying FDR 5%). For GBM, 18 out of the 45 mutationally enriched CATH-FunFams remain 
following BH correction, leading to the set of 18 MutFams for GBM.
MutFam, Miller and CGC genes. MutFam: For each of the 22 cancers, we identified the top 25% of mutated 
genes for each MutFam. Our total MutFam gene set (n = 472) is the union of gene sets from all 22 cancers ana-
lysed. We then obtained sets of genes from other methods for comparison.
CGC: We used a subset of the full cancer driver gene list from Wellcome-Sanger Cancer Gene Census54 com-
prising those annotated as having missense mutations, resulting in 232 known driver genes; other mutation types 
may also have been annotated in these genes, e.g. frameshifts or deletions.
Miller: Genes identified from the Miller method10 obtained via download of the full results table from the 
MutationAligner website69. We then filtered the list to obtain those genes with significant domain hotspot res-
idues (p < 0.05) resulting in 271 genes that contain at least one significant Pfam domain hotspot. We used this 
strategy because it gave a sensible number of genes that were deemed significant according to their analysis. The 
Miller set was chosen for comparison with MutFam as it is comprehensive and has been derived using a similar 
domain family based approach and because it provides the MutationAligner web resource for exploration and 
analysis of mutation hotspots in Pfam domain families. It has also been used in other comparative studies.
Functional enrichment scores, network properties and protein structure analyses. Dispersion 
measure for genes mapped to a Protein-Protein Interaction (PPI) network. We measured the dispersion of genes 
on a network using DS-Score, adapted from Menche et al.39 to give an overall proximity measurement for all of 
the genes in each dataset. Significance was assessed by comparison of the MutFam DS-Score with the average 
DS-Score obtained from 1000 sets of genes (n = 472, i.e. number of MutFam drivers) randomly selected from the 
STRING v10 protein-protein interaction network38.
GO term enrichment. Enrichment in GO-Slim terms was obtained for each gene set using the PANTHER online 
tool, testing for statistical over representation in GO-Slim Biological Process with P ≤ 0.0170.
Functional Interaction Networks. We analysed our MutFam gene set for pathway enrichment and pathway prox-
imity. These MutFam gene sets were mapped to a Functional Interaction Network (FIN) using the ReactomeFIViz 
tool56, which provides a curated set of both known and predicted functional protein interactions. Unlike the 
dispersion network measure outlined previously, which uses a protein-protein interaction network, Reactome 
FI uses the more specific pathway annotations of Reactome71 and allows better identification of functional rela-
tionships between proteins. For each FIN, proteins were clustered into modules using the inbuilt community 
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detection tool and each module analysed for enrichment in GO biological processes (FDR < 0.005). To compare 
the ability of different methods to identify putative driver genes, we compared the biological processes identified 
by using either MutFam or Miller gene sets. For an additional study focusing on gliomas, we obtained putative 
driver gene lists specific to the cancer types GLI, LGG and GBM and analysed these separately.
Calculation of mutations clustered on structures. We also separately calculated a set of pan-cancer MutFams 
using 800,704 somatic missense mutations from any whole exome or genome tumour sample, without any group-
ing by cancer type, to give 541 MutFams (p < 0.05, permutation test with Benjami-Hochberg correction). Note 
that this pan-cancer set is larger than the combination of the 22 cancer types, as it includes many rare cancers, 
each with very few tumour samples. We use this pan-cancer set to provide the largest possible dataset for 3D 
clustering, as mutations from different cancers clustering near a given functional site are likely to have similar 
functional impact. This larger dataset allows for increased detection of significantly enriched clusters. Mutations 
in the pan-cancer MutFams were mapped to their CATH representative domain PDB structures, where available. 
For the 541 MutFams in pan-cancer, 167 contained relatives with experimentally characterised structures. The 
representative structures selected from these FunFams had good resolution and the highest cumulative structural 
similarity to all other structures in the FunFam. For each representative structure, we tested for 3D clusters of 
mapped MutFam mutations. For each amino acid in the PDB chain with at least one mutation, we counted how 
many nearby (<5Å) residues had at least one mutation, then tested whether nearby mutation counts for each 
residue were significantly different to the expected values arising from permutation testing. For each MutFam, 
we assigned all of the observed mutations to residues in the PDB structure at random and with equal probability, 
and then calculated the observed mutation counts near each residue as above. Following 5000 such permuted 
structure trials for each MutFam, 3D clusters were defined per MutFam as the residues having an observed nearby 
mutation count more than 2σ above the mean value for that residue over all permutations. Clustering was done 
using strict thresholds and only where at least one relative in the CATH-FunFam was structurally characterised. 
In future updates clustering would be performed using additional 3D models to expand the data set. We previ-
ously published this method (“MutClust”)11 and a similar method has also been independently described43.
Calculation of distance distributions of mutation and clusters to functional sites. We used an in-house method to 
measure the closest atomic distance between a mutated residue and a functional site residue; cumulative density 
function (CDF) distributions are plotted for these distances for each mutation dataset. Significance was tested 
with respect to neutral mutations for each disease type using Fisher’s exact test, with 8Å cut-off for mutation to 
site distance and p < 0.01 considered significant (as used in Gao et al.30). For clusters of mutations, proximity 
analysis was performed using the closest atomic distance between each residue defined as a mutation in a cluster 
and the nearest functional site residue. In addition to this filtering, for positions with multiple mutations, one 
mutation was selected at random as described in Gao et al.30.
Odds ratio calculation. Odds ratios were calculated for the distance distributions of cancer mutations to func-
tional sites by comparison with neutral mutations using Fisher’s exact test with 8Å as the upper bound for prox-
imity; test based on Gao et al.30.
Scoring MutFam genes by predicted functional impact. The total MutFam gene set (472 genes) was 
annotated to find those most likely to have functional consequences using: (1) genes in common with those pre-
dicted using Miller method; (2) genes in common with CGC; (3) genes in cancer-related GO functional modules 
(defined below) and (4) genes from MutFams containing a 3D cluster near a functional site (defined above in sec-
tion: “Calculation of mutations clustered on structures”). Additionally, as some MutFams occur in multiple cancer 
types and the MutFam enrichment factor is different in each, we calculated a mean enrichment factor for all can-
cers containing the given MutFam and used this to rank genes having the same score in the list of putative drivers.
GO modules. MutFam genes are classified as being in a GO module if present in any of the functionally enriched 
GO modules listed in Supplementary Tables 5–8,12 and 13. There are 71 genes classified as in MutFams and in a 
GO module.
Data Availability
All data generated during this study is included in this published article, its Supplementary Information Files and 
online at: https://paulashford.github.io/mutfam.github.io/.
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